Humanoids Are About to Get a Public Market Price

Unitree Robotics priced its Shanghai STAR Market IPO at 150.8 yuan a share on August 6, 2026, implying a valuation of roughly 61 billion yuan — about $9.04 billion. It is selling 40.45 million new shares, roughly 10% of the enlarged share count, raising approximately 6.1 billion yuan. Subscriptions opened August 10, with listing expected as early as August 20.

When it lists, the Hangzhou company becomes the first humanoid robot maker on mainland China's stock market — and the first anywhere to have its valuation set, revised, and argued over every trading day.

That is a bigger event for the sector than the money involved.

The private market has never been tested

Humanoid robotics has raised approximately $8.6 billion in 2026 alone, already about 1.8 times the total for all of 2025, with the year only half over. Figure AI has raised around $2.34 billion at a $39 billion valuation. Apptronik, NEURA Robotics, Galbot, and UBTECH have each raised roughly $1 billion or more. The UK's Humanoid raised $152 million at $1.35 billion in July, alongside a large deployment agreement with Schaeffler.

Every one of those numbers was set in a private negotiation between a founder and a small number of investors, most of whom cannot sell for years. None has been marked against a public order book. There is no short interest, no quarterly disclosure obligation, no analyst forced to publish a discounted cash flow that someone else can attack.

That is a fine arrangement for funding a technology through its expensive adolescence. It is a poor mechanism for finding out what the technology is worth.

Unitree's listing introduces the missing mechanism. From August 20, roughly, there is a live quote on a humanoid manufacturer — and every private round in the sector will be argued against it.

What the prospectus actually shows

Unitree's filing gives the sector something it has largely lacked: audited revenue.

2025 revenue more than quadrupled to 1.7 billion yuan — roughly $240 million. Within that, humanoid robot sales reached 867.8 million yuan, overtaking the quadrupedal robots that made the company famous.

That crossover is the most important line in the document. Unitree built its business on four-legged robots — research platforms, inspection units, and the dancing quadrupeds that made it a viral fixture. The bipeds were the demo. As of 2025, the demo outsells the business.

It is also worth being precise about what those humanoid sales represent. Unitree's strategy has been aggressive price positioning: units priced far below Western competitors, sold heavily into research labs, universities, integrators, and developers. That is a genuine market with genuine revenue, and it is not the same market as the general-purpose labor automation that justifies a $39 billion private valuation elsewhere.

Which raises the question the public market will now answer: is Unitree's ~$9 billion a discount to Figure's $39 billion because Unitree is a hardware supplier to researchers rather than a labor-replacement platform — or is Figure's number a private-market artifact that a public quote would not support?

Both readings are defensible today. In about a week, one of them starts accumulating evidence.

Why the venue matters

Listing on the STAR Market rather than Hong Kong or New York is a strategic choice as much as a regulatory one. The STAR board was built for exactly this profile — domestic hard-tech companies with revenue growth and heavy R&D — and it has been receptive to valuations that a US listing committee would question.

It also positions Unitree squarely inside China's industrial policy. The country has designated humanoid robotics a strategic sector, and a domestic listing gives state-linked and institutional capital a straightforward instrument. The World Robot Conference opens in Beijing on August 19 — the day before Unitree's expected debut — with more than 300 exhibitors. The scheduling is unlikely to be accidental.

For Western competitors, the read-through is uncomfortable and familiar. Unitree will have permanent, liquid access to public capital, a domestic supply chain, and cost structure advantages, while Figure and Apptronik continue raising private rounds at valuations that require them to eventually justify multiples against a listed comparable trading at a fraction of theirs.

The risk of price discovery

Public markets are unsentimental about hardware companies with thin gross margins and long deployment cycles. Unitree will now report quarterly. Every unit-economics question that private investors accepted as premature becomes a line item somebody models.

If the stock trades well, it validates the sector and pulls the next wave of humanoid listings forward. If it trades poorly — or trades brilliantly for two months and then de-rates as the first quarterly disclosures land — the entire private mark-to-model complex above it gets repriced.

That is the trade the sector has just accepted on everyone's behalf. Humanoid robotics has spent three years being valued on demonstration videos and total-addressable-market arithmetic. Starting around August 20, one company in it gets valued on a bid and an ask.

Everything else in the category will be measured against that number, whether its founders want it to be or not.